Q-omics provides the consensus-scored SNORD6 profile across patient tissues and cancer cell-line models. SNORD6 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SNORD6 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, SNORD6 RNA expression shows 18,076 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KIRC, and UVM as cancer lineages where SNORD6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORD6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORD6 survival associations across molecular data types. SNORD6 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORD6 RNA expression–survival associations across cancer types. High SNORD6 expression shows unfavorable associations in ACC, KIRP, KIRC and KICH, but favorable associations in UCS and READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SNORD6 RNA expression.
This table summarizes SNORD6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORD6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORD6 shows higher tumor expression in KIRC, COAD, HNSC, CHOL, STAD and READ. The KIRC box plot shows higher SNORD6 RNA expression in tumor versus normal tissue (log2 FC = +1.369, t-test p < 0.001).
This table shows molecular features associated with SNORD6 in patient tissues and cancer cell lines. In patient samples, SNORD6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
